Braunwald's Heart Disease remains your indispensable source for definitive, state-of-the-art
answers on every aspect of contemporary cardiology. Edited by Drs. Robert O. Bonow …

Myocardial hypertrophy is a morphological adaptive response to chronic work overload
imposed on the heart. It has been categorized into two distinct basic types: concentric …

Angiotensin converting enzyme (ACE) inhibitors which have active moieties excreted mainly
in urine require adjustment of either the dose or the interval between doses in patients with …

BACKGROUND In the Survival and Ventricular Enlargement (SAVE) trial, recurrent
myocardial infarction (MI) was the most important predictor of a poor outcome and conferred …

Left ventricular dysfunction can be improved with angiotensin-converting-enzyme inhibition
started 1 week after myocardial infarction or later. To see whether earlier intervention may …

Antihypertensive agents have been shown to differ markedly in their effects on the
development and regression of cardiac hypertrophy. In view of possible trophic properties of …

Objectives. This study was conducted to test the hypothesis that angiotensin-converting
enzyme inhibition may lessen myocardial ischemia in patients with microvascular angina …

Through the multiple actions of angiotensin II (AII), the renin‐angiotensin system (RAS)
participates in cardiovascular homeostasis. Angiotensin II acts by binding to specific …

Recently there has been extensive development of orally active angiotensin converting
enzyme (ACE) inhibitors in addition to those already marketed, for example, captopril …

Angiotensin II elicits contractile responses in the coronary arteries and myocardial tissue,
which suggests that blockade of the renin-angiotensin system by specific agents should lead …